Overall verdict
Sell
1.8/10
1-year performance
+901.55%
Score breakdown
Up 901.6% over 1 year, 57% of the 52-week range.
Strongest: Financial strength 2.4/10. Weakest: Shareholder return 0.0/10.
Circio Holding ASA, a biotechnology company, develops novel circular RNA expression technology for gene and cell therapy. The company is developing TG01, a cancer vaccine targeting driver mutations, which is in three clinical trials for multiple myeloma, and pancreatic and lung cancer; and circVec circRNA vector platform, a modular genetic cassette for biogenesis of multifunctional circRNAs in human cells.
It has a research collaboration with United Immunity Co., Ltd. for the development of vivo CAR-Macrophage (CAR-M) therapy; and Suzhou GenAssist Therapeutics Co., Ltd. to develop circVec-enhanced AAV vectors engineered for in vivo cell therapy and low dose systemic gene therapy. The company was formerly known as Targovax ASA and changed its name to Circio Holding ASA in May 2023. Circio Holding ASA was incorporated in 2010 and is based in Oslo, Norway.
Sector
Health Care
Industry
Biotechnology
Primary listing
Osl
Norway
CEO
Dr. Erik Digman Wiklund
Founded
2010
Employees
9
Revenue / employee
0 NOK
Next earnings
November 17, 2026 (estimated)
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
15.70 NOK
52-week low
0.91 NOK
1-year performance
901.55%
Rising
Year-to-date performance
728.87%
Rising
Drawdown
-40.70%
Major drawdown
Position in the 52-week range
57% of range
ROIC -25.6%, ROE -25.6%.
Net margin
—
Sector -207.84%|S&P 13.40%
Gross margin
—
Return on equity (ROE)
-25.55%
Negative
Sector -57.88%|S&P 17.06%
Return on invested capital (ROIC)
-25.55%
Negative
Free cash flow margin (FCF)
—
Revenue to net income
Growth
0.0/10Revenue (trailing 12 months)
0 NOK
Revenue growth (1y)
—
Revenue growth (3y)
-100.00%
Declining
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.8x|S&P 23.6x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 15.0x|S&P 15.5x
PEG
—
Sector -0.08|S&P 0.91
Market cap
2.7Md NOK
Financial strength
2.4/10net debt/EBITDA 8.6x.
Net debt / EBITDA
8.6x
Stretched
Gearing (net debt / equity)
-103.88%
Net cash
Cash
549M NOK
Cash / market cap
20.24%
Very solid
Interest coverage
-19.4x
Stretched
Net debt
-549M NOK
Equity
528M NOK
Closed daily candles, 2 years
Last close on November 11, 2026: 9.30 NOK
- MM2010.44
- MM5011.10
- MM2008.26
- RSI 1434.5
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+13.45%
200-day average slope, 3 months
+61.23%
50-day average slope, 1 month
+0.81%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
2.81 % per day
Volatility change
-37.77%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -0.34 (1) | -0.34 (1) | 0 (1) | -92 (1) | -85 (1) |
| 2027 | -0.31 (1) | -0.31 (1) | 0 (1) | -110 (1) | -91 (1) |
Amounts in millions of NOK, EPS in NOK per share. In brackets, the number of analysts. Consensus as of October 26, 2026.
Same sub-industry: 772 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LRMR | 5.6 | N/A | 284M USD | Not meaningful (loss) | — | — | -135.7 % | 0.8x | -55.0 % | -21.3 % | ||
| 2 | FYB | 4.8 | 3.2 | 290M USD | Not meaningful (loss) | -41.0 % | -36.2 % | -6.2 % | -4.2x | -2.2 % | -30.3 % | ||
| 3 | ALERS | 4.3 | 4.4 | 287M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 7.1 % | ||
| 4 | NWBO | 3.5 | 4.0 | 290M USD | Not meaningful (loss) | -1736.4 % | 535.4 % | 275.6 % | -1.3x | -17.2 % | -32.6 % | ||
| 5 | 688426 | 2.9 | 3.2 | 299M USD | Not meaningful (loss) | -35.4 % | 24.1 % | -6.0 % | — | -0.5 % | -35.6 % | ||
| 6 | SABS | 2.9 | 0.9 | 280M USD | Not meaningful (loss) | -6088.9 % | -100.0 % | -34.5 % | 1.2x | -21.0 % | -1.3 % | ||
| 7 | LCTX | 2.7 | 1.5 | 281M USD | Not meaningful (loss) | -246.6 % | -61.3 % | -57.7 % | 1.9x | -8.7 % | -43.3 % | ||
| 8 | A174900 | 2.4 | 2.6 | 298M USD | Not meaningful (loss) | -328.3 % | 51.4 % | -40.6 % | 0.2x | -3.0 % | -10.7 % | ||
| 9 | CRNA | 1.8 | 0.4 | 284M USD | Not meaningful (loss) | — | — | -25.6 % | 8.6x | -2.0 % | 901.6 % |
